Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 356

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials

Open access
Adamstein, Nicholas H, MacFadyen, Jean G, Rose, Lynda M, Glynn, Robert J, Dey, Amit K, Libby, Peter, Tabas, Ira A, Mehta, Nehal N, Ridker, Paul M·2021·European Heart Journal

Abstract

Aims: The neutrophil–lymphocyte ratio (NLR) is a readily available inflammatory biomarker that may associate with atherosclerosis and predict cardiovascular (CV) events. The aims of this study are to determine whether the NLR predicts incident major adverse cardiovascular events (MACE) and is modified by anti-inflammatory therapy. Methods and results: Baseline and on-treatment NLRs were calculated from complete blood counts among 60 087 participants randomized in the CANTOS, JUPITER, SPIRE-1, SPIRE-2, and CIRT trials to receive placebo or canakinumab, rosuvastatin, bococizumab, or methotrexate, respectively, and followed up for MACE. All analyses were performed first in CANTOS, and then externally validated in the other four trials. For the five trials, hazard ratios for major CV events and mortality comparing NLR quartiles were computed using Cox proportional hazards models, and the effect of each randomized intervention on the NLR was evaluated in comparison to placebo. The NLR modestly correlated with interleukin-6, C-reactive protein, and fibrinogen levels but minimally with lipids. In all five randomized trials, baseline NLR predicted incident CV events and death; the per-quartile increase in risk of MACE was 20% in CANTOS [95% confidence interval (CI) 14–25%, P < 0.0001], 31% in SPIRE-1 (95% CI 14–49%, P = 0.00007), 27% in SPIRE-2 (95% CI 12–43%, P = 0.0002), 9% in CIRT (95% CI 0.2–20%, P = 0.045), and 11% in JUPITER (95% CI 1–22%, P = 0.03). While lipid-lowering agents had no significant impact on the NLR, anti-inflammatory therapy with canakinumab lowered the NLR (P < 0.0001). Conclusion: The NLR, an easily obtained inflammatory biomarker, independently predicts CV risk and all-cause mortality, and is reduced by interleukin-1β blockade with canakinumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa1034

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 356

Metadata

Authors
Adamstein, N. H., MacFadyen, J. G., Rose, L. M., Glynn, R. J., Dey, A. K., Libby, P., Tabas, I. A., Mehta, N. N., & Ridker, P. M.
Venue
European Heart Journal
Published
2021-01-08
Volume
42
Issue
9
Pages
896-903
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3119981920
Cited by
356
References
32
FWCI
12.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa1034
The paper
Adamstein, N. H., MacFadyen, J. G., Rose, L. M., Glynn, R. J., Dey, A. K., Libby, P., Tabas, I. A., Mehta, N. N., & Ridker, P. M. (2021). The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa1034

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.